Vallari K. Kothari

https://assets.montefioreeinstein.org/profiles/images/Kothari_Vallari_MD_2x.jpg

First Name

Vallari

Last Name

Kothari

NPI

1942685292

Faculty ID

19464

CMO Specialties

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

P1014619

Is Open Scheduling

Off

Sarah A. Reda

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/d2a5b100-504e-11ef-931e-8373c6b518fb.jpg

First Name

Sarah

Last Name

Reda

NPI

1003304510

Faculty ID

17794

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

186405

Visit Type ID

2499

Is Open Scheduling

On

Beatrice Y. Wong

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b4012680-c3c5-11eb-9ea2-7374238588d1.jpg

First Name

Beatrice

Last Name

Wong

NPI

1033656541

Faculty ID

16257

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

95560

Visit Type ID

2499

Is Open Scheduling

On

Yaron Tomer

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e3b1f380-8c61-11ed-9474-c3e3b839843d.jpg

First Name

Yaron

Last Name

Tomer

NPI

1982662334

Faculty ID

14884

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Yaron Tomer is the Marilyn and Stanley M. Katz Dean at Albert Einstein College of Medicine and Chief Academic Officer at Montefiore Medicine.</p>
<p>He received his M.D. degree magna cum laude from the Sackler School of Medicine of Tel Aviv University and trained in Internal Medicine at Sheba Medical Center, Israel, and in Endocrinology at the Icahn School of Medicine at Mount Sinai in New York. Prior to joining Montefiore Einstein in March 2016, he was Chief of the Division of Endocrinology, Diabetes, and Bone Disease at Mount Sinai.</p>
<p>Dr. Tomer has served on the editorial boards of <em>Endocrinology </em>and <em>The Journal of Clinical Endocrinology and Metabolism</em>, among others. He is a member of the American Society for Clinical Investigation and a Fellow of the American College of Physicians. Dr. Tomer is the recipient of several prestigious awards, including the American Thyroid Association&rsquo;s Sidney H. Ingbar Distinguished Lectureship Award, as well as its Van Meter Award.</p>
<h3>Research</h3>
<p>Dr. Tomer&rsquo;s research program focuses on the immunogenetic, epigenetic, and environmental mechanisms underlying thyroid autoimmunity, and type 1 diabetes, and on targeting these mechanisms in order to develop novel therapies. His group made several discoveries including identifying new genes and mechanisms underlying the strong association between type 1 diabetes and autoimmune thyroiditis; demonstrating that CD40 and thyroglobulin are major susceptibility genes for thyroid autoimmunity; identifying a unique amino acid variant in the peptide binding pocket of HLA-DR that is key for the development of thyroid autoimmunity; dissecting the epigenetic mechanisms by which polymorphisms in the thyroglobulin and TSHR genes interact with environmental agents (e.g. viruses) to trigger thyroid autoimmunity; and identifying a novel small molecule that can block antigen presentation in autoimmune thyroiditis.</p>
<h3>Current Projects</h3>
<ol role="list">
<li><strong>Genetic and epigenetic studies in thyroid autoimmunity</strong><br />The Tomer lab mapped several susceptibility genes for autoimmune thyroid diseases (AITD) including CD40, thyroglobulin, and TSHR. Recent data suggest that variants in regulatory regions of some of these genes interact epigenetically with environmental factors (e.g., viral infections) to trigger disease. Current studies are using epigenomic screening, including whole genome methylation studies and ChiP-seq analyses to study these genetic-epigenetic interactions.</li>
<li><strong>Epigenetic studies in type 1 diabetes</strong><br />Similar studies are utilizing epigenomic screening to analyze epigenetic interactions between known type 1 diabetes susceptibility genes and interferon alpha, a key cytokine secreted during viral infections.</li>
<li><strong>Translational studies in autoimmune thyroiditis (AITD) and type 1 diabetes</strong><br />The Tomer lab discovered that the presence of arginine at position beta-74 of the peptide binding pocket of HLA-DR is critical for the development of AITD. This discovery led to a translational project aimed at blocking thyroid antigen presentation to T-cells by the arginine beta-74 HLA-DR peptide binding pocket as a potential therapy for AITD. Recently, the Tomer lab identified a small molecule, Cepharanthine, that can block antigen presentation and suppress AITD in mouse models. Similar studies are performed in type 1 diabetes where the aim is to block the HLA-DQ8 peptide binding pocket from presenting insulin peptides to T-cells as a novel strategy to treat autoimmune diabetes.</li>
<li><strong>Genetic and functional analyses of autoimmune polyglandular syndrome (APS) type 3</strong><br />The co-occurrence of type 1 diabetes and autoimmune thyroiditis in the same individual is considered a variant of the APS type 3 syndrome. The Tomer lab discovered several new susceptibility genes for APS3. The lab is now analyzing the mechanisms by which these genes predispose to disease.</li>
<li><strong>The role of viruses in triggering autoimmune thyroiditis and type 1 diabetes</strong><br />Certain infections, such as hepatitis C, are associated with autoimmune thyroiditis and diabetes. Current studies are aimed at dissecting the mechanisms by which interferon alpha, the primary cytokine secreted during viral infections, can trigger autoimmune thyroiditis and diabetes in genetically susceptible individuals.</li>
</ol>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol role="list">
<li>Menconi F, Monti MC, Greenberg DA, Oashi T, Osman R, Davies TF, Ban Y, Jacobson EM, Concepcion ES, Li CW, <span class="underline">Tomer Y</span>. Molecular amino acid signatures in the MHC class II peptide binding pocket predispose to autoimmune thyroiditis in humans and in mice. Proc Natl Acad Sci USA 2008; 105: 14034-14039.</li>
<li>Jacobson EM, Yang H, Menconi F, Wang R, Osman R, Skrabanek L, Li CW, Fadlalla M, Gandhi A, Chaturvedi V, Smith EP, Schwemberger S, Osterburg A, Babcock GF, <span class="underline">Tomer Y</span>. Employing a recombinant HLA-DR3 expression system to dissect MHC II-thyroglobulin peptide dynamism: A genetic, biochemical, and reverse immunological perspective. J Biol Chem 2009; 284: 34231-34243.</li>
<li>Villano MJ, Huber AK, Greenberg DA, Golden BK, Concepcion E, <span class="underline">Tomer Y</span>. Autoimmune thyroiditis and diabetes: Dissecting the joint genetic susceptibility in a large cohort of multiplex families. J Clin Endocrinol Metab 2009; 94: 1458-1466.</li>
<li>Menconi F, Osman R, Monti MC, Greenberg DA, Concepcion ES, <strong>Tomer Y</strong>. Shared molecular amino acid signature in the HLA-DR peptide binding pocket predisposes to both autoimmune diabetes and thyroiditis. Proc Natl Acad Sci USA 2010; 107: 16899-16903.</li>
<li>Menconi F, Huber A, Osman R, Concepcion E, Jacobson EM, Stefan M, David, CS, <span class="underline">Tomer Y</span>. Tg.2098 is a major human thyroglobulin T-cell epitope. J Autoimmun 2010; 35: 45-51.</li>
<li>Stefan M, Jacobson EM, Huber AK, Greenberg DA, Li CW, Skrabanek L, Concepcion E, Fadlalla M, Ho K, <span class="underline">Tomer Y</span>. Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism. J Biol Chem 2011; 286: 31168-31179.</li>
<li>Huber AK, Finkelman FD, Li CW, Concepcion E, Smith E, Jacobson E, Latif R, Keddache M, Zhang W, <span class="underline">Tomer Y</span>. Genetically driven target tissue overexpression of CD40: A novel mechanism in autoimmune disease. J Immunol 2012; 189: 3043-3053.</li>
<li>Stefan M, Wei C, Lombardi A, Li CW, Concepcion ES, Inabnet WB 3rd, Owen R, Zhang W, <span class="underline">Tomer Y</span>. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc Natl Acad Sci USA 2014; 111: 12562-12567.</li>
<li><span class="underline">Tomer Y</span>, Dolan LM, Kahaly G, Divers J, D&rsquo;Agostino Jr. RB, Imperatore G, Dabelea D, Marcovina S, Black MH, Pihoker C, Hasham A, Hammerstad SS, Greenberg DA, Lotay V, Zhang W, Monti MC, Matheis N. Genome wide identification of new genes and pathways in patients with autoimmune thyroiditis and type 1 diabetes. J Autoimmun 2015; 60: 32-39.</li>
<li>Li CW, Menconi F, Osman R, Mezei M, Jacobson EM, Concepcion E, David CS, Kastrinsky DB, Ohlmeyer M, <strong>Tomer Y</strong>. Identifying a small molecule blocking antigen presentation in autoimmune thyroiditis. J Biol Chem 2016; 291: 4079-4090.</li>
<li>Li CW, Osman R, Menconi F, Concepcion ES, <span class="underline">Tomer Y</span>. Flexible peptide recognition by HLA-DR triggers specific autoimmune T-cell responses in autoimmune thyroiditis and diabetes. J Autoimmun 2017; 76: 1-9.</li>
<li>Faustino LC, Lombardi A, Madrigal-Matute J, Owen RP, Libutti SK, <span class="underline">Tomer Y</span>. Interferon alpha triggers autoimmune thyroid diseases via lysosomal-dependent degradation of thyroglobulin. J Clin Endocrinol Metab 2018; 103: 3678-3687.</li>
<li>Stefan-Lifshitz, M, Karakose E, Cui L, Ettela A, Yi Z, Zhang W, <span class="underline">Tomer Y</span>. Epigenetic modulation of &beta;-cells by interferon-&alpha; via PNPT1-miR26a-TET2 triggers autoimmune diabetes. JCI Insight 2019; 4: e126663.</li>
<li>Li CW, Osman R, Menconi F, Concepcion E, <span class="underline">Tomer Y</span>. Cepharanthine blocks TSH receptor peptide presentation by HLA-DR3: Therapeutic implications to Graves&rsquo; disease. J Autoimmun 2020; 108: 102402.</li>
<li>Lombardi, A, Concepcion E, Hou H, Arib H, Mezei M, Osman R, <span class="underline">Tomer Y</span>. Retro-inverso D-peptides as a novel targeted immunotherapy for type 1 diabetes. J Autoimmune 2020; 115: 102543.</li>
<li>Li CW, Sachidanandam R, Jayaprakash A, Yi Z, Zhang W, Stefan-Lifshitz M, Concepcion E, <span class="underline">Tomer Y</span>. Identification of new rare variants associated with familial autoimmune thyroid diseases by deep sequencing of linked loci. J Clin Endocrinol Metab 2021; 12: 691781.</li>
<li>Ye J, Stefan-Lifshitz M, <span class="underline">Tomer Y</span>. Genetic and environmental factors regulate the type 1 diabetes gene CTSH via differential DNA methylation. J Biol Chem 2021; 296: 100774.</li>
<li>Li CW, Osman R, Menconi F, Faustino LC, Kim K, Clarke OB, Hou H, <span class="underline">Tomer Y</span>. Cepharanthine blocks presentation of thyroid and islet peptides in a novel humanized autoimmune diabetes and thyroiditis mouse model. Front Immunol 2021; 12: 796552.</li>
</ol>

EMR ID

81697

Is Open Scheduling

Off

Vafa Tabatabaie

https://assets.montefioreeinstein.org/profiles/images/Tabatabaie_Vafa_MD_2x.jpg

First Name

Vafa

Last Name

Tabatabaie

NPI

1861789976

Faculty ID

13732

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Vafa Tabatabaie received her medical degree from Shahid Beheshti Medical University in Tehran, Iran. After several years of research on thyroid cancer in Toronto, Canada, she came to Montefiore in 2007, initially as a clinical observer and then as a researcher in the Division of Endocrinology under the direction of Drs. Norman Fleischer and Martin Surks. She graduated from the Internal Medicine Residency Program in 2011, during which her enthusiasm and teaching skills were recognized with the Award for Outstanding House Officer in Internal Medicine. She then completed her Endocrinology Fellowship in 2013 and joined the Einstein Montefiore Division of Endocrinology faculty later that year.</p>
<p>Dr. Tabatabaie is the Clinical Director for Division of Endocrinology.&nbsp;She is also the Director of Fracture Liaison Services, a multi-disciplinary team of Endocrinologist, Geriatricians and Orthopedic Surgeons focused on secondary prevention of osteoporotic fractures. &nbsp;Dr Tabatabaie is one of the founding members of Transgender Interest Group at Montefiore/Einstein. Her clinical research interests include endocrine issues in the elderly, especially metabolic bone disease and osteoporosis, as well as thyroid cancer. She has contributed to the field of endocrinology by writing journal articles, presenting posters at national endocrine meetings, and mentoring medical students, residents and fellows. In recognition of her contributions to medical education, she was accepted into Leo M Davidoff Society in 2019. She also received Department of Medicine's Humanism Award in 2018.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong>Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort</strong></p>
<p>Cancers,&nbsp;<span style="caret-color: #5b616b; color: #5b616b; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">2021 Mar 23;13(6):1464</span></p>
<p>&nbsp;</p>
<p><strong>Are We Responding Effectively to Bone Mineral Density Loss and Fracture Risk in People with Epilepsy?</strong></p>
<p>Epilepsia Open, 2020 Apr 14;5(2): 240-247</p>
<p>&nbsp;</p>
<p><strong>Changes in Bone Mineral Density During 5 Years of Adjuvant Treatment in Premenopausal Breast Cancer Patients</strong></p>
<p>Breast Cancer Research and Treatment, 2020 Feb 19</p>
<p>&nbsp;</p>
<p><strong>Treatment of Diabetic Ketoacidosis and The Weekend Effect at an Urban Tertiary-Care Center</strong></p>
<p>Endocrine Practice,&nbsp;<span style="caret-color: #5b616b; color: #5b616b; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">2020 Jun 2;26(6):634-641</span></p>
<p>&nbsp;</p>
<p><strong>Thyroid Storm Presenting as Psychosis</strong></p>
<p>Journal of Investigative Medicine High Impact Case Reports, May 2018</p>
<p>&nbsp;</p>
<p><strong>Medical Optimization of Lumbar Fusion in the Osteoporotic Patient</strong></p>
<p>Archives of Osteoporosis, 2018 March 14: 13 (1): 26</p>
<p>&nbsp;</p>
<p><strong>Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels</strong></p>
<p>Journal Of Clinical Endocrinology and Metabolism. 2016 Aug; 101 (8): 3096-104</p>
<p>&nbsp;</p>
<p><strong>Effects of Testosterone Treatment in Older Men</strong></p>
<p>New England Journal of Medicine, 2016 Feb 18: 374 (7): 611-24</p>
<p>&nbsp;</p>
<p><strong>Recruitment and Screening for the Testosterone Trials</strong></p>
<p>The Journals of Gerontology, 2015 Sep, 70(9): 1105-11</p>
<p>&nbsp;</p>
<p><strong>Association of Sex Hormones with Sexual Function, Vitality, and Physical Function of Symptomatic Older Men with Low Testosterone Levels at Baseline in the Testosterone Trials</strong></p>
<p>Journal of Clinical Endocrinology and Metabolism, 2015 Mar, 100(3):1146-55</p>
<p>&nbsp;</p>
<p><strong>Exceptional Longevity is Associated with Decreased Reproduction</strong></p>
<p>Aging, 2011 Dec, 3(12):1202-5</p>
<p>&nbsp;</p>
<p><strong>Influence of Age and Primary Tumor Size on the Risk for Residual/Recurrent Well-Differentiated Thyroid Carcinoma</strong></p>
<p>Head and Neck, 2009 Jun; 31(6):782-8</p>
<p>&nbsp;</p>
<p><strong>Post-Challenge Hyperglycemia in Older Adults is Associated with Increased Cardiovascular Risk Profile</strong></p>
<p>Journal of Clinical Endocrinology and Metabolism, 2009 May, 94(5):1595-601</p>
<p>&nbsp;</p>
<p><strong>Prognostic Value of Postsurgical Stimulated Thyroglobulin Levels after Initial Radioactive Iodine Therapy in Well-Differentiated Thyroid Carcinoma</strong></p>
<p>Head and Neck, 2008 Jun; 30(6):693-700</p>

EMR ID

5083

Biography

<p>Dr. Vafa Tabatabaie received her medical degree from Shahid Beheshti University of Medical Sciences in Tehran, Iran. After several years of research on thyroid cancer in Toronto, Canada, she came to Montefiore in 2007 as a researcher in the Division of Endocrinology under the direction of Drs. Norman Fleischer and Martin Surks. She graduated from the Internal Medicine Residency Program in 2011, during which her enthusiasm and teaching skills were recognized with the Award for Outstanding House Officer in Internal Medicine, and she completed the Endocrinology Fellowship Program in 2013. She joined the Einstein Montefiore Division of Endocrinology faculty later that year.</p><p>Dr. Tabatabaie is Director of the Fracture Liaison Service at Montefiore Medical Center. Her clinical research interests include endocrine issues in the elderly, especially metabolic bone disease and osteoporosis, as well as thyroid cancer.</p>

Visit Type ID

2499

Is Open Scheduling

On

Martin I. Surks

https://assets.montefioreeinstein.org/profiles/images/physphoto/Surks_Martin_I_MD_2835.jpg

First Name

Martin

Last Name

Surks

NPI

1891885794

Faculty ID

4372

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Current Activities:</strong>&nbsp;</p>
<ul>
<li>Program Director, Division of Endocrinology and Metabolism, Albert Einstein College of Medicine</li>
<li>Director of the Endocrinology Clinic, Montefiore Medical Center</li>
<li>Consultant in thyroid disease and general endocrinology</li>
<li>Research Mentor</li>
</ul>
<p>&nbsp;<strong>Clinical Practice:</strong></p>
<p>Dr. Surks restricts his consultative practice to disorders of the thyroid gland, and to other disorders of general endocrinology such as diseases of the pituitary, parathyroid glands, gonads, adrenal glands, and to metabolic bone disease.</p>
<p>&nbsp;<strong>Research Interests:</strong></p>
<p>Historical Summary:&nbsp;Major contributions from thyroid research at Montefiore Medical Center began nearly 100 years ago with findings of Dr. David Marine, Chairman of Pathology, that deficiency of iodine was associated with development of goiter and iodine deficiency diseases that affected hundreds of millions of people around the world His studies initiated iodine supplementation to salt in the US, and elimination of this major health problem. A Medical Physics laboratory, the progenitor of Nuclear Medicine Departments, was established in 1945 and was widely known for the earliest studies of radioactive iodine use to treat hyperthyroidism and thyroid cancer. From 1960 to 1976, Dr. Jack Oppenheimer published widely on thyroid hormone measurements and metabolism, discovered the nuclear receptor for thyroid hormone and studied its effects on different gene products</p>
<p>Most of Dr. Surks&rsquo; research has focused on thyroid physiology, pathophysiology and diseases. For the last five years, he has studied subclinical thyroid diseases, and the characterization of the reference range for serum TSH in human beings.&nbsp;</p>

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Surks is a thyroid disease expert with 40 years of experience in basic and clinical research, education and patient care. In addition to thyroid disorders, his clinical practice focuses on conditions of the pituitary, parathyroid and adrenal glands and on metabolic bone disease. His recent research has involved subclinical thyroid diseases and determining a reference range for TSH (thyroid-stimulating hormone) levels in people.&nbsp;</p>
<p>A noted educator, Dr. Surks led a collaborative project that culminated in a generic &ldquo;gold standard&rdquo; curriculum for endocrinology training programs that is used nationwide. He is author of <em>The Thyroid Book</em> and editor of the <em>Atlas of Clinical Endocrinology Volume I: Thyroid Diseases</em>. He has served on the editorial boards of several journals, including <em>Endocrinology</em> and the<em> Journal of Clinical Endocrinology &amp; Metabolism</em>, and currently is on the editorial board of <em>Thyroid</em>.&nbsp;</p>
<p>Dr. Surks is a member of the American Society for Clinical Investigation and the Association of American Physicians. He is a former president of the American Thyroid Association and the Association of Program Directors in Endocrinology, Diabetes and Metabolism. His awards include the American Thyroid Association&rsquo;s Distinguished Service Award and the Van Meter Award, and the Sidney H. Ingbar Distinguished Service Award of the Endocrine Society. He was also awarded a Mastership by the American College of Physicians in recognition of his contributions to research, education, and teaching.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol type="1">
<li>Cases, J.A., Wenig, B.M., Silver, C.E., Surks, M.I. Recurrent acute suppurative thyroiditis in an adult due to a pyriform-sinus (4th branchial pouch) fistula. J Clin Endocrinol &amp; Metab 85:953-956, 2000.</li>
<li>Cases, J.A., Surks, M.I. Changing role of scintigraphy in the evaluation of thyroid nodules; Seminars in Nuclear Medicine, Volume 30:81-87, 2000.</li>
<li>Surks, M.I., &lsquo;Hyperthyroidism&rsquo;; &lsquo;Hypothyroidism&rsquo;; &lsquo;Goiter&rsquo;; &lsquo;Iodine&rsquo;;;Thyroid Disorders&rsquo;; &lsquo;Thyroid Function Tests&rsquo;; in Encyclopedia of Public Health; Editor-in-Chief, Breslow, L., McMillan Reference USA, New York, 2002</li>
<li>Surks, M.I., Hyperthyroidism, Conn&rsquo;s Current Therapy, 2003 Eds Rakel and Bope; Elsevier Science (USA) 717-720.</li>
<li>Dubenko, M., Breining, W., Surks, M.I. &nbsp; Sclerosing lymphocytic lobulitis of the breast &nbsp; in a patient with Graves&rsquo; disease. &nbsp;2003 &nbsp;THYROID 13:309-311.</li>
<li>Rizza RA, Vigersky RA, Rodbard HW, Ladenson PW, Young WF Jr, Surks MI, Kahn R, Hogan PF. 2003. A model to determine workforce needs for endocrinologists in the United &nbsp;States until 2020. J Clin Endocrinol Metab 88: 1979-1987.</li>
<li>Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. &nbsp;Subclinical thyroid disease: Scientific Review and Guidelines for Diagnosis and Management. JAMA, 2004; 291: 228-238.&nbsp;</li>
<li>Col, NF, Surks MI. and Daniels GH: Subclinical thyroid disease: Clinical Applications. &nbsp; JAMA &nbsp;2004; 291: 239 &ndash; 243.</li>
<li>Senzel L, Surks MI, and Buettner C: Polyuria and abdominal pain in a &nbsp; young &nbsp; Jamaican woman. Laboratory Medicine, 2004; 35: 100 &ndash; 103.</li>
<li>Surks MI: Response: to &lsquo;Subclinical Thyroid Dysfunction: A joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association and The Endocrine Society&rsquo; THYROID, 2005,15:32-33. &nbsp; &nbsp; &nbsp;&nbsp;</li>
<li>Surks MI: COMMENTARY: Subclinical Thyroid dysfunction: A joint statement on Management from the American Association of Clinical Endocrinologists, the American &nbsp;Thyroid &nbsp; &nbsp;Association, and The Endocrine society. J Clin Endocrinol Metab 2005, 90: 586-. 588</li>
<li>Surks, MI, Goswami G, Daniels GH: &nbsp;CONTROVERSY IN CLINICAL &nbsp;ENDOCRINOLOGY: The thyrotropin reference range should remain unchanged. J ClinEndcrinol Metab 2005; 5489 &ndash; 5496.</li>
<li>Surks, MI &nbsp;Hypothyroidism: New issues and controversies. The Endocrinologist. 2006.16: 203-208.</li>
<li>Meyerovitch J, Rotman-Pikiely P, Sherf M, Battat E, Levy Y, Surks MI: Serum &nbsp; &nbsp;thyrotropin (TSH) measurements in the community: 5-year follow-up in a large network of primary care physicians. Archives Internal Med &nbsp; 2007; 167: 1533 &ndash; 1538</li>
<li>Surks MI, Hollowell JG. &nbsp;Age-specific distribution of serum TSH and antithyroid antibodies in the United States population; Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol &amp; Metab &nbsp;2007; 92: 4575-4582</li>
<li>Surks MI, Hollowell JG: &nbsp;Age-specific distribution of serum TSH and antithyroid antibodies in the United States Population; Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol and Metab 2007; 92: 4575-4582.</li>
<li>Surks, MI. 2008. Should the upper limit of the normal reference range for TSH be lowered? Nature Clinical Practice: Endocrinology and Metabolism 4: 370-371</li>
<li>Surks MI &nbsp;2008 Concise Review: TSH reference limits: Emerging concepts and implications for the prevalence of subclinical hypothyroidism. Clin Thyroidology 20:4-5.</li>
<li>Atzmon G, Barzilai N, Hollowell JG, Surks MI, Gabriely I: 2009 Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab 94:1251-1254.</li>
<li>Atzmon G, Barzilai N, Surks MI, Gabriely I &nbsp;2009 &nbsp; Genetic Predisposition to Elevated &nbsp;Serum Thyrotropin is Associated with Exceptional Longevity. J Clin Endocrinol Metab &nbsp;94: 4768-4775</li>
<li>Surks MI &nbsp; &nbsp;2011 &nbsp; Milestones in Thyroid Research at Montefiore Medical Center: 1920 &ndash; 2011: History and Personal Reflections--in press</li>
<li>Cases, J.A., Wenig, B.M., Silver, C.E., Surks, M.I. Recurrent acute suppurative thyroiditis in an adult due to a pyriform-sinus (4th branchial pouch) fistula. J Clin Endocrinol &amp; Metab 85:953-956, 2000.</li>
<li>Cases, J.A., Surks, M.I. Changing role of scintigraphy in the evaluation of thyroid nodules; Seminars in Nuclear Medicine, Volume 30:81-87, 2000.</li>
<li>Surks, M.I., &lsquo;Hyperthyroidism&rsquo;; &lsquo;Hypothyroidism&rsquo;; &lsquo;Goiter&rsquo;; &lsquo;Iodine&rsquo;;;Thyroid Disorders&rsquo;; &lsquo;Thyroid Function Tests&rsquo;; in Encyclopedia of Public Health; Editor-in-Chief, Breslow, L., McMillan Reference USA, New York, 2002</li>
<li>Surks, M.I., Hyperthyroidism, Conn&rsquo;s Current Therapy, 2003 Eds Rakel and Bope; Elsevier Science (USA) 717-720.</li>
<li>Dubenko, M., Breining, W., Surks, M.I. &nbsp; Sclerosing lymphocytic lobulitis of the breast &nbsp; in a patient with Graves&rsquo; disease. &nbsp;2003 &nbsp;THYROID 13:309-311.</li>
<li>Rizza RA, Vigersky RA, Rodbard HW, Ladenson PW, Young WF Jr, Surks MI, Kahn R, Hogan PF. 2003. A model to determine workforce needs for endocrinologists in the United &nbsp;States until 2020. J Clin Endocrinol Metab 88: 1979-1987.</li>
<li>Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ. &nbsp;Subclinical thyroid disease: Scientific Review and Guidelines for Diagnosis and Management. JAMA, 2004; 291: 228-238.&nbsp;</li>
<li>Col, NF, Surks MI. and Daniels GH: Subclinical thyroid disease: Clinical Applications. &nbsp; JAMA &nbsp;2004; 291: 239 &ndash; 243.</li>
<li>Senzel L, Surks MI, and Buettner C: Polyuria and abdominal pain in a &nbsp; young &nbsp; Jamaican woman. Laboratory Medicine, 2004; 35: 100 &ndash; 103.</li>
<li>Surks MI: Response: to &lsquo;Subclinical Thyroid Dysfunction: A joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association and The Endocrine Society&rsquo; THYROID, 2005,15:32-33. &nbsp; &nbsp; &nbsp;&nbsp;</li>
<li>Surks MI: COMMENTARY: Subclinical Thyroid dysfunction: A joint statement on Management from the American Association of Clinical Endocrinologists, the American &nbsp;Thyroid &nbsp; &nbsp;Association, and The Endocrine society. J Clin Endocrinol Metab 2005, 90: 586-. 588</li>
<li>Surks, MI, Goswami G, Daniels GH: &nbsp;CONTROVERSY IN CLINICAL &nbsp;ENDOCRINOLOGY: The thyrotropin reference range should remain unchanged. J ClinEndcrinol Metab 2005; 5489 &ndash; 5496.</li>
<li>Surks, MI &nbsp;Hypothyroidism: New issues and controversies. The Endocrinologist. 2006.16: 203-208.</li>
<li>Meyerovitch J, Rotman-Pikiely P, Sherf M, Battat E, Levy Y, Surks MI: Serum &nbsp; &nbsp;thyrotropin (TSH) measurements in the community: 5-year follow-up in a large network of primary care physicians. Archives Internal Med &nbsp; 2007; 167: 1533 &ndash; 1538</li>
<li>Surks MI, Hollowell JG. &nbsp;Age-specific distribution of serum TSH and antithyroid antibodies in the United States population; Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol &amp; Metab &nbsp;2007; 92: 4575-4582</li>
<li>Surks MI, Hollowell JG: &nbsp;Age-specific distribution of serum TSH and antithyroid antibodies in the United States Population; Implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol and Metab 2007; 92: 4575-4582.</li>
<li>Surks, MI. 2008. Should the upper limit of the normal reference range for TSH be lowered? Nature Clinical Practice: Endocrinology and Metabolism 4: 370-371</li>
<li>Surks MI. 2008 Editorial: New evidence against lowering the thyrotropin reference limits. Clin Thyroidology 20: 8</li>
<li>Surks MI &nbsp;2008 Concise Review: TSH reference limits: Emerging concepts and implications for the prevalence of subclinical hypothyroidism. Clin Thyroidology 20:4-5.</li>
<li>Atzmon G, Barzilai N, Hollowell JG, Surks MI, Gabriely I: 2009 Extreme longevity is associated with increased serum thyrotropin. J Clin Endocrinol Metab 94:1251-1254.</li>
<li>Atzmon G, Barzilai N, Surks MI, Gabriely I &nbsp;2009 &nbsp; Genetic Predisposition to Elevated &nbsp;Serum Thyrotropin is Associated with Exceptional Longevity. J Clin Endocrinol Metab &nbsp;94: 4768-4775</li>
<li>Surks MI &nbsp; &nbsp;2011 &nbsp; Milestones in Thyroid Research at Montefiore Medical Center: 1920 &ndash; 2011: History and Personal Reflections--in press</li>
</ol>

EMR ID

3515

Biography

<p>Martin I. Surks, MD, MACP, is an attending physician, Professor, Medicine, Pathology and Laboratory Medicine and Program Director Emeritus, Endocrines Clinic (1976-2018) at Montefiore Einstein. Dr. Surks&rsquo; clinical practice focuses on disorders of the thyroid gland and other disorders of general endocrinology such as diseases of the pituitary, parathyroid glands, gonads and adrenal glands, and metabolic bone disease.</p><p>After completing his Bachelor of Arts at Columbia College in 1956, Dr. Surks pursued his medical education at New York University - Bellevue College, earning his Doctor of Medicine in 1960. He began his postdoctoral training at Montefiore and completed it at Veterans Administration Hospital in 1963. Dr. Surks then returned to Montefiore to complete a postdoctoral research fellowship in arthritis and metabolic diseases in 1964.</p><p>The majority of Dr. Surks&rsquo; research focuses on thyroid physiology, pathophysiology and diseases. Most recently, he has studied subclinical thyroid diseases and the characterization of the reference range for serum TSH in human beings. He has shared his research in major peer-reviewed journals, and through editorials, abstracts, books and letters, having published more than 200 peer-reviewed papers and 2 books. He has also served on the editorial boards of several medical journals including <em>Endocrine Research, Thyroid</em> and the <em>Journal of Clinical Endocrinology and Metabolism</em>.</p><p>Dr. Surks is a Master of the American College of Physicians, a Diplomate of the National Board of Medical Examiners and a member of the American Association of Clinical Endocrinologists. He is past President of the American Thyroid Association and the Association of Program Directors of Endocrinology and Metabolism. Dr. Surks has earned many accolades throughout his career, including the Distinguished Service Award from the American Thyroid Association, the Sidney H. Ingbar Distinguished Service Award from the Endocrine Society and the Physician Recognition Award from the American Medical Association.</p>

Is Open Scheduling

On

Nisha Suda

https://assets.montefioreeinstein.org/profiles/images/physphoto/Suda_Nisha_MD_420x504.jpg

First Name

Nisha

Last Name

Suda

NPI

1114269438

Faculty ID

16139

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Suda's&nbsp;clinical focus has been on the treatment of patients with metabolic dysfunctions, including pituitary and neuroendocrine disorders, osteoporosis and metabolic calcium and phosphate diseases, diabetes, weight management, thyroid hormone dysfunction, infertility, hypogonadism, and polycystic ovary syndrome.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

As a researcher, Dr. Suda focuses on quality improvement projects related to glycemic management in inpatient and outpatient settings.

Elsevier Profile

EMR ID

14496

Biography

<p>Nisha Suda, MD, MHA, is an Attending Physician at Montefiore and an Assistant Professor in Internal Medicine, Endocrinology and Metabolism at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2018, her clinical focus has been on the treatment of patients with metabolic dysfunctions, including pituitary and neuroendocrine disorders, osteoporosis and metabolic calcium and phosphate diseases, diabetes, weight management, thyroid hormone dysfunction, infertility, hypogonadism, and polycystic ovary syndrome.</p><p>In 2007, Dr. Suda received her Bachelor of Arts in biology at Cornell University College of Arts &amp; Sciences. She continued her education at Cornell University and received her Master of Health Administration in 2009. Following this, she attended the University of Medicine and Dentistry of New Jersey, where she received her Doctor of Medicine in 2013. Dr. Suda began her postgraduate training at Rutgers New Jersey Medical School with a residency in internal medicine, which she completed in 2016. From 2016 to 2018, Dr. Suda completed a fellowship in clinical endocrinology and metabolism at Yale University.</p><p>As a researcher, Dr. Suda focuses on quality improvement projects that relate to glycemic management in both inpatient and outpatient settings. Dr. Suda is an experienced researcher, having worked with a number of teams at Cornell and Yale. Her work has been published in many peer-reviewed journals, articles, and books.</p><p>Dr. Suda is board certified in internal medicine and endocrinology and metabolism, and is also a member of the Endocrine Society, the American Association of Clinical Endocrinologists&rsquo;, and the American Thyroid Association.</p>

Visit Type ID

2499

Is Open Scheduling

On

Simona Stefan

https://assets.montefioreeinstein.org/profiles/images/physphoto/Stefan_Simona_MD_LC_420x504.jpg

First Name

Simona

Last Name

Stefan

NPI

1932524915

Faculty ID

16368

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

114470

Visit Type ID

2499

Is Open Scheduling

On

Zocdoc Link

Saachi Sachdev

https://assets.montefioreeinstein.org/profiles/images/physphoto/Saachi_Sachdev_MD_LC_420x504.jpg

First Name

Saachi

Last Name

Sachdev

NPI

1689917908

Faculty ID

16657

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

PubMed.gov URL

EMR ID

122813

Biography

<p>Saachi Sachdev, MD, is Director, Dr. Martin Surks FCC Endocrinology Clinic at Montefiore Einstein and Assistant Professor, Medicine at our Albert Einstein College of Medicine. Dr. Sachdev practices general endocrinology and sees patients for conditions including primary hyperparathyroidism, osteoporosis, pituitary disorders, hypo/hyperthyroidism, adrenal gland disorders, Polycystic ovary syndrome (PCOS), and type 2 diabetes. She has established a pediatric-to-adult endocrinology care transition pathway to support young adult patients with non-type 1 diabetes diagnoses navigating the vulnerable transition to adult care.</p><p>After obtaining her Bachelor of Arts at Harvard University in 2009, Dr. Sachdev earned her Doctor of Medicine at Columbia University College of Physicians & Surgeons in 2013. She then completed an internship in medicine at NewYork-Presbyterian Hospital-Columbia University Medical Center in 2014, followed by her residency in medicine at the same institution in 2016. In 2020, Dr. Sachdev completed an endocrinology, diabetes and metabolism fellowship at the Hospital of the University of Pennsylvania.</p><p>Dr. Sachdev helps lead the Division of Endocrinology's quality improvement initiatives and has established a quality improvement curriculum for the endocrinology fellowship program. Her research aligns with her clinical focus and has been published in several peer-reviewed journals and abstracts.</p><p>Dr. Sachdev is board certified in Endocrinology, Diabetes, and Metabolism by the American Board of Internal Medicine. She is a member of the Endocrine Society and the American Diabetes Association.</p>

Visit Type ID

2499

Is Open Scheduling

On

Anne Marie Reynolds

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Anne Marie

Last Name

Reynolds

NPI

1912047895

Faculty ID

2596

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

3652

Is Open Scheduling

Off